Exact Sciences Corporatio... (EXAS)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Exact Sciences Corporation Statistics
Share Statistics
Exact Sciences Corporation has 185.08M shares outstanding. The number of shares has increased by 1.95% in one year.
Shares Outstanding | 185.08M |
Shares Change (YoY) | 1.95% |
Shares Change (QoQ) | 0.17% |
Owned by Institutions (%) | 99.19% |
Shares Floating | 182.06M |
Failed to Deliver (FTD) Shares | 2.64K |
FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 10.29M, so 5.56% of the outstanding shares have been sold short.
Short Interest | 10.29M |
Short % of Shares Out | 5.56% |
Short % of Float | 5.64% |
Short Ratio (days to cover) | 5.31 |
Valuation Ratios
The PE ratio is -10.06 and the forward PE ratio is -158314.3. Exact Sciences Corporation's PEG ratio is -0.03.
PE Ratio | -10.06 |
Forward PE | -158314.3 |
PS Ratio | 3.75 |
Forward PS | 2.2 |
PB Ratio | 4.31 |
P/FCF Ratio | 138.84 |
PEG Ratio | -0.03 |
Enterprise Valuation
Exact Sciences Corporation has an Enterprise Value (EV) of 15.28B.
EV / Earnings | -14.85 |
EV / Sales | 5.54 |
EV / EBITDA | 1660.48 |
EV / EBIT | 1660.48 |
EV / FCF | 204.92 |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 1.15.
Current Ratio | 2.15 |
Quick Ratio | 1.92 |
Debt / Equity | 1.15 |
Total Debt / Capitalization | 53.42 |
Cash Flow / Debt | 0.08 |
Interest Coverage | -0.34 |
Financial Efficiency
Return on equity (ROE) is -0.43% and return on capital (ROIC) is 0.18%.
Return on Equity (ROE) | -0.43% |
Return on Assets (ROA) | -0.17% |
Return on Capital (ROIC) | 0.18% |
Revenue Per Employee | 424.44K |
Profits Per Employee | -158.29K |
Employee Count | 6.50K |
Asset Turnover | 0.47 |
Inventory Turnover | 5.17 |
Taxes
Income Tax | 7.30M |
Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -22.17% in the last 52 weeks. The beta is 1.24, so Exact Sciences Corporation's price volatility has been higher than the market average.
Beta | 1.24 |
52-Week Price Change | -22.17% |
50-Day Moving Average | 56.2 |
200-Day Moving Average | 56.37 |
Relative Strength Index (RSI) | 37.02 |
Average Volume (20 Days) | 2.11M |
Income Statement
In the last 12 months, Exact Sciences Corporation had revenue of 2.76B and earned -1.03B in profits. Earnings per share was -5.59.
Revenue | 2.76B |
Gross Profit | 1.92B |
Operating Income | 9.20M |
Net Income | -1.03B |
EBITDA | 9.20M |
EBIT | 9.20M |
Earnings Per Share (EPS) | -5.59 |
Balance Sheet
The company has 600.89M in cash and 2.75B in debt, giving a net cash position of -2.15B.
Cash & Cash Equivalents | 600.89M |
Total Debt | 2.75B |
Net Cash | -2.15B |
Retained Earnings | -4.50B |
Total Assets | 5.93B |
Working Capital | 966.34M |
Cash Flow
In the last 12 months, operating cash flow was 210.54M and capital expenditures -135.99M, giving a free cash flow of 74.55M.
Operating Cash Flow | 210.54M |
Capital Expenditures | -135.99M |
Free Cash Flow | 74.55M |
FCF Per Share | 0.4 |
Margins
Gross margin is 69.55%, with operating and profit margins of 0.33% and -37.29%.
Gross Margin | 69.55% |
Operating Margin | 0.33% |
Pretax Margin | -37.03% |
Profit Margin | -37.29% |
EBITDA Margin | 0.33% |
EBIT Margin | 0.33% |
FCF Margin | 2.7% |
Dividends & Yields
EXAS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -11.35% |
FCF Yield | 0.82% |
Analyst Forecast
The average price target for EXAS is $70, which is 42.1% higher than the current price. The consensus rating is "Buy".
Price Target | $70 |
Price Target Difference | 42.1% |
Analyst Consensus | Buy |
Analyst Count | 18 |
Scores
Altman Z-Score | 2.17 |
Piotroski F-Score | 5 |